Clover Health Investments saw its shares climb sharply this week after a federal court decision forced the Centers for Medicare & Medicaid Services to recalculate the Star Rating on the company's core Medicare Advantage plan. The upgrade to 4.5 stars from 3.5 stars has significant implications for the insurer's financial outlook in 2027, as quality bonus payments are directly tied to these ratings.
On Wednesday, Clover shares closed at $4.89, up 13.99% on the day, pushing the company's market capitalization to roughly $2.58 billion. The stock continued to rally in premarket trading Thursday, reaching $5.29, up another 8.18%, according to StockAnalysis data. The 52-week high, which stood at $5.14, was briefly breached during the surge.
The catalyst for the move was a June 10 filing with the Securities and Exchange Commission, in which Clover disclosed that CMS had recalculated the 2026 Star Rating for Contract H5141, its primary PPO plan, to 4.5 stars. This followed a final judgment on May 29 in the U.S. District Court for the Southern District of Georgia, which granted in part Clover Insurance Company's motion for summary judgment in its lawsuit against HHS. The court ordered CMS to recalculate the rating, and on June 9, CMS informed Clover of the new 4.5-star rating.
The importance of this upgrade cannot be overstated for Clover. The company noted that the PPO contract now covers over 97% of its Medicare Advantage members, making the rating change highly concentrated in its business. The HMO plan, Contract H8010, was not part of the litigation and retains its 4.0-star rating for 2026. CMS uses Star Ratings on a one-to-five scale to evaluate plan quality, and plans with four stars or higher qualify for increased benchmark payments and larger rebates. Plans achieving 4.5 stars receive an even greater rebate than those at exactly four stars, according to KFF.
Clover's financial performance has been improving. In the first quarter, the company reported revenue of $749.2 million, up 62.1% year-over-year, with GAAP net income of $27.3 million. It ended the quarter with 155,773 Medicare Advantage members and adjusted EBITDA of $40.3 million. Management has guided for GAAP net income between $0 million and $20 million and adjusted EBITDA of $50 million to $70 million for 2026. CEO Andrew Toy stated in May that the company expects its first full year of GAAP net income profitability in 2026.
Analysts have taken note of the improved outlook. Canaccord's Richard Close raised his price target on Clover to $4.20 from $3.20 on June 4, maintaining a Buy rating. However, with shares now trading above that target, some caution is warranted. The market may be pricing in the rating upgrade before concrete evidence emerges of its impact on the bottom line. Key risks include medical claims exposure, the need for 2027 bids to be approved, and ongoing regulatory scrutiny of Medicare Advantage quality bonus payments, which KFF estimates at a minimum of $12.7 billion for 2025.
Investors will now focus on how the 4.5-star rating translates into Clover's 2027 benefit design, pricing, and ultimately earnings for the PPO plan that covers nearly all its members. The company has not yet disclosed the financial impact of the alternate bids it has been instructed to submit at the higher rating. The next few months will be critical as Clover navigates the regulatory and competitive landscape to capitalize on this significant advantage.
